ARTICLE | Company News
Aslan, NCCS to study GI cancers
July 17, 2015 1:31 AM UTC
Aslan Pharmaceuticals Pte. Ltd. (Singapore) and the National Cancer Centre Singapore signed a memorandum of understanding to jointly study gastrointestinal cancers that are disproportionately prevalent in Asia.
Aslan and NCCS plan to study gastric cancer, hepatocellular carcinoma, and cholangiocarcinoma. They intend to conduct preclinical studies of combination therapies that include the company's ASLAN001 and ASLAN002 as well as clinical trials of novel treatments, and plan to host a series of disease symposiums. ...